Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/47843
• EU PAS number:
  EUPAS43167
• Study ID:
  47843
• Official title and acronym:
  Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of COPD maintenance therapy with Tiotropium Bromide/Olodaterol(TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual: 24/04/2020

Study start date

Actual: 26/02/2021

Date of final study report

Planned: 30/06/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable